scholarly journals Pathogenesis of Ovarian Clear Cell Adenofibroma, Atypical Proliferative (Borderline) Tumor, and Carcinoma: Clinicopathologic Features of Tumors with Endometriosis or Adenofibromatous Components Support Two Related Pathways of Tumor Development

2011 ◽  
Vol 2 ◽  
pp. 94-106 ◽  
Author(s):  
Chengquan Zhao ◽  
Lee Shu-Fune Wu ◽  
Ross Barner
Keyword(s):  
Clear Cell ◽  
Tumor Development ◽  
Borderline Tumor ◽  
Clinicopathologic Features ◽  
Clear Cell Adenofibroma

scholarly journals Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhiyang Zhang ◽  
Penglian Gao ◽  
Zhengqi Bao ◽  
Linggong Zeng ◽  
Junyi Yao ◽  
...  
Keyword(s):  
Overall Survival ◽  
Distant Metastasis ◽  
Survival Data ◽  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Molecular Characteristics ◽  
Clinicopathologic Features ◽  
Ki 67

ObjectiveClear cell carcinoma (CCC) of the endometrium is an uncommon yet aggressive tumor. Few cohort studies are reporting the overall survival time of CCC patients. This study aimed to retrospectively analyze the clinicopathologic features, molecular characteristics and survival data of 27 endometrial CCC patients to improve the understanding of CCC.MethodsThe clinicopathologic features, molecular characteristics and survival data total of 27 CCC patients admitted to the BBMU affiliated hospital (Anhui, China) between January 2005 and December 2018 were retrospectively analyzed. Kaplan-Meier method was used to analyze the prognosis-related factors.ResultsThe median age of the patients was 60 years (range; 39 to 81 years). The average tumor size was 3.8 cm (range; 0.8 to 13.0cm). Myometrial infiltration greater than 50% was reported in 55.6% of the patients, while the Ki-67 index greater than 50% was reported in 70.4% of the patients. The patients’ FIGO (2009) surgical stages were as follows: 18 I, 3 II, 4 III, and 2 IV. Besides, 7 (25.6%) patients had lymphovascular invasion, 3 (11.1%) patients with distant metastasis, including 1 patient with bone metastasis, and 2 with liver metastasis. Adjuvant treatment included 7 with chemotherapy alone, 9 with radiotherapy alone, and 9 with both radiotherapy and chemotherapy. The median overall survival time from the time of CCC diagnosis was 56 months. ER and PR showed negative expression and P16 showed patchy immunostaining. 18 (63%) cases showed Napsin A positive expression. Loss of MSH2, MSH6 and PTEN were seen in 5, 4 and 7 cases respectively. All cases showed HER-2/nue negative expression.ConclusionCCC is a rare and invasive tumor. Age of diagnosis, FIGO stage, tumor size, myometrial infiltration, lymphovascular invasion, distant metastasis, Ki-67 index and P53 expression are important indicators to evaluate patient’s prognosis (P = 0.048, P < 0.001, P = 0.016, P = 0.043, P = 0.001, P < 0.001, P = 0.026, and P = 0.007, respectively). CCC has a worse prognosis than endometrioid carcinoma (P = 0.002), and there is no significant difference when compared with uterine papillary serous carcinoma (P = 0.155).

scholarly journals A case of ovarian clear cell borderline tumor treated by laparoscopic restaging surgery

2013 ◽  
Vol 29 (1) ◽  
pp. 110-114
Author(s):  
Kuniaki Toriyabe ◽  
Hirohiko Tanaka ◽  
Tokihiro Senda ◽  
Masako Ito ◽  
Miho Izawa ◽  
...  
Keyword(s):  
Clear Cell ◽  
Borderline Tumor

Single center validation of neutrophil-to-lymphocyte ratio in localized and metastatic clear cell renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 696-696
Author(s):  
Kevin Richard Melnick ◽  
Dattatraya H Patil ◽  
Amir Ishaq Khan ◽  
Frances Y Kim ◽  
Mersiha Torlak ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Kidney Cancer ◽  
Renal Cell ◽  
Validation Cohort ◽  
Clear Cell ◽  
Independent Predictor ◽  
Prognostic Scores ◽  
Clinicopathologic Features

696 Background: The neutrophil-to-lymphocyte ratio (NLR) has been evaluated as a serum marker of inflammation and oncologic prognosis. In renal cell carcinoma (RCC), a higher preoperative NLR is associated with aggressive clinicopathologic features and is an independent predictor of poor survival. This study builds upon our institution’s prior work with the NLR in metastatic RCC and examines a larger validation cohort that includes localized disease. It also compares the predictive power of the NLR to established kidney cancer prognostic scores. Methods: Our kidney cancer database provided patients with clear cell RCC who underwent nephrectomy from January 2001 to June 2017 and had a documented preoperative NLR within 15 days prior to surgery. The optimal threshold of NLR was determined using receiver operating characteristic (ROC) curve and sensitivity-specificity trade-off analysis. Kaplan-Meier curves and logistic regression analysis were performed to assess the significance and independence of preoperative NLR in predicting OS. Finally, the prognostic ability of NLR was compared to current prognostic scores through chi-square analysis of their respective c-indices. Results: The 441 patient cohort was comprised of 361 patients with localized and/or regional disease and 80 patients with distant metastases. NLR values among all participants ranged from 0.4 to 74.0 (median 3.1). ROC analysis defined an optimal preoperative NLR threshold of 3.5. On multivariate analysis, after adjusting for clinicopathologic features and distant metastatic disease, a NLR ≥ 3.5 was found to be a significant and independent predictor of overall survival (HR = 1.41, 95% CI 1.05-1.91 & p value = 0.024). Our data also revealed no statistically significant difference between the c-indices of NLR and the UISS, SSIGN, or Leibovich scores in predicting survival. Conclusions: In our validation cohort of patients with both metastatic and non-metastatic clear cell RCC, our data show that a preoperative NLR ≥ 3.5 is a significant and independent predictor of overall survival in patients undergoing nephrectomy and is comparable to other established prognostic tools in RCC.

An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway

2009 ◽  
Vol 455 (3) ◽  
pp. 261-270 ◽  
Author(s):  
Sohei Yamamoto ◽  
Hitoshi Tsuda ◽  
Kozue Suzuki ◽  
Masashi Takano ◽  
Seiichi Tamai ◽  
...  
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenofibroma

scholarly journals Association between atypical endometriosis and ovarian malignancies in the real world

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Kyeong A So ◽  
Sung Ran Hong ◽  
Nae Ri Kim ◽  
Eun Jung Yang ◽  
Seung-Hyuk Shim ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Borderline Tumor ◽  
Endometrioid Adenocarcinoma ◽  
Ovarian Malignancy ◽  
Histopathological Results ◽  
Endometriosis Surgery ◽  
Atypical Endometriosis

Abstract Background To evaluate the clinical outcome of atypical endometriosis and its association with ovarian malignancy. Methods This retrospective study included patients diagnosed with atypical endometriosis between January 2001 and December 2017. All patients had received surgical treatment for ovarian tumor. The clinical characteristics and histopathological results of all patients were reviewed. Results Atypical endometriosis was diagnosed in 101 patients. We analyzed 98 patients with a mean age of 34.8 years (range: 16–58 years). Ten patients (10.2%) had previously undergone endometriosis surgery more than once. In total, 12 (12.2%) patients had atypical endometriosis-associated ovarian malignancy—nine had carcinomas and three had borderline tumor. The tumors were pathologically classified as follows: five, clear cell carcinomas; two, endometrioid adenocarcinomas; one, mixed clear cell and endometrioid adenocarcinoma; one, seromucinous carcinoma; two, mucinous borderline tumors; and one, seromucinous borderline tumor. Conclusion Atypical endometriosis is most frequently associated with clear cell carcinoma and endometrioid adenocarcinoma. To identify the risk of ovarian malignancy and manage patients with endometriosis, diagnosing atypical endometriosis and recognizing its precancerous potential are important.

Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma

2018 ◽  
Vol 26 (6) ◽  
pp. 578-580
Author(s):  
Zhiwei Yin ◽  
Stephen Peters ◽  
Ravi Chokshi ◽  
Debra Heller
Keyword(s):  
Clear Cell ◽  
Malignant Potential ◽  
Clear Cell Adenocarcinoma ◽  
Precursor Lesion ◽  
Borderline Tumors ◽  
Low Malignant Potential ◽  
Adenocarcinoma Of The Ovary ◽  
Clear Cell Adenofibroma

Ovarian clear cell adenofibroma is uncommon, and borderline clear cell adenofibroma (low malignant potential) is extremely rare. Borderline clear cell adenofibromas may represent the precursor lesion of clear cell adenocarcinoma of the ovary, but this has not been established. We present a case of a woman in her mid-50s with a clear cell adenofibroma ranging from benign to borderline to frankly invasive. While some clear cell adenocarcinomas are thought to arise from endometriosis, this range of findings supports the theory that some ovarian clear cell adenocarcinomas originate from borderline tumors.

scholarly journals Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Eriko Nakamura ◽  
Yuichiro Sato ◽  
Sayaka Moriguchi ◽  
Atsushi Yamashita ◽  
Takashi Higo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tumor Cells ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
English Literature ◽  
Borderline Tumor ◽  
Borderline Tumors ◽  
First Case ◽  
Napsin A ◽  
Unusual Combination

Ovarian seromucinous borderline tumors (SMBTs) are rare. They architecturally resemble serous borderline tumors but are much more frequently associated with endometriosis. The coexistence of other tumors with seromucinous tumors is also extremely rare. Here, we report an unusual combination of bilateral ovarian SMBT and clear cell carcinoma associated with polypoid endometriosis of the colon, in a 62-year-old woman. There was no transitional lesion between the two tumors. Immunohistochemistry showed different staining patterns in tumor components. Seromucinous tumor cells were positive for estrogen receptor (ER) and progesterone receptor (PgR) but negative for Napsin A, p504S, and HNF1B. Clear cell tumor cells were positive for Napsin A and p504S and focally positive for HNF1B but negative for ER and PgR. Loss of ARID1A expression was not observed in SMBTs, clear cell tumors, or endometriosis. These findings suggest that these tumors arose from separate endometriosis foci and collided within the same ovary. To the best of our knowledge, this is the first case of this unusual combination of ovarian seromucinous tumor and clear cell carcinoma to be reported in the English literature.

scholarly journals Frozen Section in the Management of Ovarian and Uterine Tumors: The Past 5 Years in a Tertiary Centre

2018 ◽  
Vol 40 (08) ◽  
pp. 458-464 ◽  
Author(s):  
Joana Aidos ◽  
Renata Veríssimo ◽  
Joana Almeida ◽  
Teresa Carvalho ◽  
Nuno Martins ◽  
...  
Keyword(s):  
Clear Cell ◽  
Frozen Section ◽  
Paraffin Section ◽  
Myometrial Invasion ◽  
High Sensitivity ◽  
Ovarian Tumors ◽  
Borderline Tumor ◽  
The Past ◽  
Tertiary Centre ◽  
Uterine Tumors

Objective Intraoperative frozen section (IFS) is a valuable resource, and its use in gynecological pathology has not been sufficiently emphasized. The main goal of the present study is to evaluate the reliability and agreement rates between IFS and the final paraffin section (PS) and determine how reliable IFS is. Methods A retrospective study of all IFSs performed on uterine tumors and suspicious adnexal masses between January 2012 and December 2016 (excluding metastases) at the department of obstetrics and gynecology of the Centro Hospitalar Tondela Viseu. Frozen versus permanent section diagnosis were compared regarding the histologic type of the tumor, and the depth of myometrial invasion. Results A total of 286 cases were eligible for the present study, including 102 (35.7%) IFSs of uterine tumors, and 184 (64.3%) IFSs of ovarian tumors. The overall rate of deferred cases was 5.2% (15/286). The accuracy of the diagnosis in cases of endometrial carcinoma was 96.25% (77/80). Among the ovarian tumors, misdiagnoses occurred in 2 cases (1.1%), corresponding to a borderline tumor (serous type) and a clear cell intracystic adenocarcinoma. Conclusion The IFS analysis plays an important role in selected situations and is associated to a high sensitivity and specificity in cases of ovarian and endometrial tumors. Its high accuracy is almost universally associated with the possibility of obtaining an optimal surgical treatment at the time of the first surgical approach.

Sign in / Sign up

Export Citation Format

Share Document